Safety and efficacy of using exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

B. Jose¹, R.E.J. Ryder¹, K.Y. Thong¹, S. Thozhukat², W. Shafiq², ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom, 
²Diabetes, Hull Royal Infirmary, Hull, United Kingdom

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton²,  ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

 ²Diabetes, Hull Royal Infirmary, Hull, UK

Problems with the NICE guideline for exenatide exposed in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton², K.A. Adamson³, D.S.Dove⁴ on behalf of the ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom

²Diabetes, Hull Royal Infirmary, Hull, United Kingdom

16.6% (1 in 6) patients who continued insulin at the time of exenatide start came off insulin in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit

K.Y. Thong¹, B. Jose¹, N. Sukumar¹, M.L. Cull¹, A. Mills¹, T. Sathyapalan², W. Shafiq², A. Rigby², C. Walton², R.E.J. Ryder¹, on behalf of the ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom

Safety and efficacy of using exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

B. Jose¹, R.E.J. Ryder¹, K.Y. Thong¹, S. Thozhukat², W. Shafiq², ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom

²Diabetes, Hull Royal Infirmary, Hull, United Kingdom

Factors accounting for variability in weight and HbA1c response to exenatide in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

R.E.J. Ryder¹ , C. Walton² , P.H. Winocour³ , ABCD nationwide exenatide audit contributors⁴

¹City Hospital, Birmingham, United Kingdom

²Hull Royal Infirmary, Hull, United Kingdom

³Queen Elizabeth II Hospital, Welwyn Garden City

⁴numerous other hospitals and diabetes centres, United Kingdom

Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

R.E.J. Ryder¹, C. Walton², P.H. Winocour³, ABCD nationwide exenatide audit contributors⁴

1 City Hospital, Birmingham, United Kingdom
2 Hull Royal Infirmary, Hull, United Kingdom
3 Queen Elizabeth II Hospital, Welwyn Garden City
4 numerous other hospitals and diabetes centres, United Kingdom

Safety and efficacy of using exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

B. Jose¹, R.E.J. Ryder¹, K.Y. Thong¹, S. Thozhukat², W. Shafiq², ABCD nationwide exenatide audit contributors

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits

KY Thong¹, P Sen Gupta², ML Cul^l2, KA Adamson³, DS Dove⁴, SV Rowles⁵, S Tarpey⁵, C Duncan⁶, J Chalmers⁶, R Harper⁷, P McDonald⁷, U Brennan⁷, C Walton⁸, REJ Ryder² 

¹School of Medicine and Pharmacology University of Western Australia, Perth, Australia